SCHEMBL6170369

SCHEMBL6170369

CCOC(=O)c1ccc([N+](=O)[O-])c(N(Cc2c(Cl)cccc2Cl)C(C)=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 7/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 6/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 3/20 0.44
PKM P14618 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
LMNA P02545 3/20 0.43
PTGER4 P35408 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
GAA P10253 2/20 0.41
MGLL Q99685 1/20 0.41
MAPK1 P28482 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6170740 0.90 KMT2A (0.46) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6170389 0.89 KMT2A (0.48) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6168812 0.85 KMT2A (0.47) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6169177 0.84 MAPT (0.50) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6170467 0.84 KMT2A (0.52) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6170395 0.82 KMT2A (0.48) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6169083 0.81 MAPT (0.49) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6171717 0.80 KMT2A (0.46) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6171240 0.80 ALDH1A1 (0.48) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6170567 0.80 ALDH1A1 (0.48) KMT2AMEN1ALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed